Trial Profile
A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Cefepime/zidebactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Wockhardt Ltd
- 25 May 2018 New trial record
- 12 May 2018 Results published in the Antimicrobial Agents and Chemotherapy.